Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
Xue-Yan DuanShu-Yan LiuDao-Gen YinPublished in: Medicine (2021)
This updated network meta-analysis reproduced the findings in the first network meta-analysis, and moreover revealed that sotagliflozin was one of the most effective drugs as for lowering MI, stroke, MACE, and HHF, whereas ertugliflozin was not. These findings will provide the according evidence regarding the usage of specific SGLT2 inhibitors and GLP-1 RAs in T2D patients for prevention of specific cardiorenal endpoints.
Keyphrases
- systematic review
- end stage renal disease
- type diabetes
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- randomized controlled trial
- atrial fibrillation
- cardiovascular disease
- physical activity
- skeletal muscle
- single cell
- patient reported outcomes
- metabolic syndrome
- brain injury
- glycemic control